Natasha S Anstee
Overview
Explore the profile of Natasha S Anstee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
311
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chua C, Loo S, Fong C, Ting S, Tiong I, Fleming S, et al.
Blood Adv
. 2025 Jan;
PMID: 39825857
Venetoclax plus azacitidine represents a key advance for older, unfit patients with acute myeloid leukemia (AML). The chemotherapy and venetoclax in elderly AML trial (CAVEAT) was first to combine venetoclax...
2.
Peng H, Jabbari J, Tian L, Wang C, You Y, Chua C, et al.
Genome Res
. 2025 Jan;
PMID: 39794120
Single-cell long-read sequencing has transformed our understanding of isoform usage and the mutation heterogeneity between cells. Despite unbiased in-depth analysis, the low sequencing throughput often results in insufficient read coverage,...
3.
Loo S, Potter N, Ivey A, ONions J, Moon R, Jovanovic J, et al.
Blood
. 2024 Sep;
144(24):2554-2557.
PMID: 39316646
Pretransplant detection of KMT2Ar measurable residual disease ≥0.001% by quantitative polymerase chain reaction was associated with significantly inferior posttransplant survival (2-year relapse-free survival 17% vs 59%; P = .001) and...
4.
Loo S, Roberts A, Anstee N, Kennedy G, He S, Schwarer A, et al.
Blood
. 2023 Aug;
142(23):1960-1971.
PMID: 37647654
Sorafenib maintenance improves outcomes after hematopoietic cell transplant (HCT) for patients with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) acute myeloid leukemia (AML). Although promising outcomes have been reported for...
5.
Sabatier M, Birsen R, Lauture L, Mouche S, Angelino P, Dehairs J, et al.
Cancer Discov
. 2023 Apr;
13(7):1720-1747.
PMID: 37012202
Significance: FLT3 mutations are found in 30% of AML cases and are actionable by tyrosine kinase inhibitors. Here, we discovered that C/EBPα regulates FA biosynthesis and protection from lipid redox...
6.
Moujalled D, Brown F, Chua C, Dengler M, Pomilio G, Anstee N, et al.
Blood
. 2022 Oct;
141(6):634-644.
PMID: 36219880
Randomized trials in acute myeloid leukemia (AML) have demonstrated improved survival by the BCL-2 inhibitor venetoclax combined with azacitidine in older patients, and clinical trials are actively exploring the role...
7.
Loo S, Dillon R, Ivey A, Anstee N, Othman J, Tiong I, et al.
Blood
. 2022 Aug;
140(22):2407-2411.
PMID: 35960851
No abstract available.
8.
Thijssen R, Diepstraten S, Moujalled D, Chew E, Flensburg C, Shi M, et al.
Blood
. 2021 Apr;
137(20):2721-2735.
PMID: 33824975
Selective targeting of BCL-2 with the BH3-mimetic venetoclax has been a transformative treatment for patients with various leukemias. TP-53 controls apoptosis upstream of where BCL-2 and its prosurvival relatives, such...
9.
Morcos M, Zerjatke T, Glauche I, Munz C, Ge Y, Petzold A, et al.
J Exp Med
. 2020 Apr;
217(6).
PMID: 32302400
The proliferative activity of aging hematopoietic stem cells (HSCs) is controversially discussed. Inducible fluorescent histone 2B fusion protein (H2B-FP) transgenic mice are important tools for tracking the mitotic history of...
10.
Nguyen H, Vandenberg C, Ng A, Robati M, Anstee N, Rimes J, et al.
Blood
. 2020 Jan;
135(13):1019-1031.
PMID: 31978211
Deregulated overexpression of MYC is implicated in the development and malignant progression of most (∼70%) human tumors. MYC drives cell growth and proliferation, but also, at high levels, promotes apoptosis....